Key result
Reducing angiotensin inhibition improves renal and mortality outcomes in older patients with CKD and HF.
Why the study?
Does reduction of angiotensin inhibition improve renal and mortality outcomes in older CKD patients with heart failure?
Does reduction of angiotensin inhibition improve renal and mortality outcomes in older CKD patients with heart failure?
In older patients with concurrent chronic kidney disease and heart failure, reducing angiotensin inhibition may improve renal and mortality outcomes.
Supports deprescribing angiotensin inhibitors in older CKD-HF patients; challenges maximal RAAS blockade guidelines and extends cardiorenal dosing evidence.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Macaulay Onuigbo (2015) studied this question. Reduction of angiotensin inhibition improved renal and mortality outcomes in older patients with chronic kidney disease and heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: